Skip to main content

Advertisement

Table 4 Choroidal neovascularization in the fellow eye developing from 0 to 24 months after baseline versus Barbazetto et al. [41]

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

  Conversions in current study (conversions/fellow eyes with dry AMD) Conversions-Barbazetto et al. [41] (conversions/fellow eyes with dry AMD) p-value
TT, 12 months 12/160 (20 %) 100/445 (22.5 %) 0.0001
TTZ, 12 months 3/80 (3.75 %) 100/445 (22.5 %) 0.00003
TT, 24 months 20/160 (12.5 %) 151/445 (33.9 %) 0.0000006
TTZ, 24 months 5/80 (6.25 %) 151/445 (33.9 %) 1 × 1.0−14
  1. TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, CFT central foveolar thickness